Skip to main content
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

July 17, 2018; 91 (3) ArticleOpen Access

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis

A multicenter study

Marloes H.J. Hagens, Jessica Burggraaff, Iris D. Kilsdonk, Marlieke L. de Vos, Niamh Cawley, Emilia Sbardella, Michaela Andelova, Michael Amann, Johanna M. Lieb, Patrizia Pantano, Birgit I. Lissenberg-Witte, Joep Killestein, Celia Oreja-Guevara, Olga Ciccarelli, Claudio Gasperini, Carsten Lukas, Mike P. Wattjes, Frederik Barkhof, For the MAGNIMS Study Group
First published June 20, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005825
Marloes H.J. Hagens
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Burggraaff
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iris D. Kilsdonk
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marlieke L. de Vos
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niamh Cawley
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilia Sbardella
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Andelova
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Amann
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna M. Lieb
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizia Pantano
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit I. Lissenberg-Witte
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joep Killestein
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celia Oreja-Guevara
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Ciccarelli
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudio Gasperini
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Lukas
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike P. Wattjes
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Barkhof
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
From the Departments of Neurology (M.H.J.H., J.B., J.K.) and Radiology and Nuclear Medicine (I.D.K., M.L.d.V., M.P.W., F.B.), MS Centre Amsterdam, and Department of Epidemiology and Biostatistics (B.I.L.-W.), VU University Medical Centre; Department of Radiology and Nuclear Medicine (I.D.K.), Onze Lieve Vrouwen Gasthuis, Amsterdam, the Netherlands; Queen Square Multiple Sclerosis Centre (N.C., O.C.) and Institutes of Neurology & Healthcare Engineering (F.B.), UCL Institute of Neurology, London, UK; Department of Neurology and Psychiatry (E.S., P.P.), Sapienza University of Rome, Italy; Department of Neurology (M. Andelova, M. Amann) and Division of Neuroradiology, Department of Radiology (M. Amann, J.M.L.), University Hospital Basel; Medical Image Analysis Centre (M. Amann), Basel, Switzerland; Istituto Neurologico Mediterraneo (P.P.), Neuromed, Pozzilli (IS), Italy; Department of Neurology (C.O.-G.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; National Institute for Health Research (O.C., F.B.), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), UK; Department of Neurosciences (C.G.), San Camillo-Forlanini Hospital, Rome, Italy; and Department of Diagnostic and Interventional Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University, Bochum, Germany.
Full PDF
Short Form
Citation
Three-Tesla MRI does not improve the diagnosis of multiple sclerosis
A multicenter study
Marloes H.J. Hagens, Jessica Burggraaff, Iris D. Kilsdonk, Marlieke L. de Vos, Niamh Cawley, Emilia Sbardella, Michaela Andelova, Michael Amann, Johanna M. Lieb, Patrizia Pantano, Birgit I. Lissenberg-Witte, Joep Killestein, Celia Oreja-Guevara, Olga Ciccarelli, Claudio Gasperini, Carsten Lukas, Mike P. Wattjes, Frederik Barkhof, For the MAGNIMS Study Group
Neurology Jul 2018, 91 (3) e249-e257; DOI: 10.1212/WNL.0000000000005825

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2179

Share

  • Article
  • Figures & Data
  • Info & Disclosures
  • CME Course
Loading

Abstract

Objective In the work-up of patients presenting with a clinically isolated syndrome (CIS), 3T MRI might offer a higher lesion detection than 1.5T, but it remains unclear whether this affects the fulfilment of the diagnostic criteria for multiple sclerosis (MS).

Methods We recruited 66 patients with CIS within 6 months from symptom onset and 26 healthy controls in 6 MS centers. All participants underwent 1.5T and 3T brain and spinal cord MRI at baseline according to local optimized protocols and the MAGNIMS guidelines. Patients who had not converted to MS during follow-up received repeat brain MRI at 3–6 months and 12–15 months. The number of lesions per anatomical region was scored by 3 raters in consensus. Criteria for dissemination in space (DIS) and dissemination in time (DIT) were determined according to the 2017 revisions of the McDonald criteria.

Results Three-Tesla MRI detected 15% more T2 brain lesions compared to 1.5T (p < 0.001), which was driven by an increase in baseline detection of periventricular (12%, p = 0.015), (juxta)cortical (21%, p = 0.005), and deep white matter lesions (21%, p < 0.001). The detection rate of spinal cord lesions and gadolinium-enhancing lesions did not differ between field strengths. Three-Tesla MRI did not lead to a higher number of patients fulfilling the criteria for DIS or DIT, or subsequent diagnosis of MS, at any of the 3 time points.

Conclusion Scanning at 3T does not influence the diagnosis of MS according to McDonald diagnostic criteria.

Glossary

CIS=
clinically isolated syndrome;
DIS=
dissemination in space;
DIT=
dissemination in time;
EDSS=
Expanded Disability Status Scale;
IQR=
interquartile range;
MAGNIMS=
Magnetic Resonance Imaging in Multiple Sclerosis;
MS=
multiple sclerosis;
PD=
proton density;
T1WI=
T1-weighted imaging;
T2WI=
T2-weighted imaging

MRI is the most sensitive tool for the detection of inflammatory demyelination in the CNS.1,–,3 Numerous studies have stressed the importance of MRI in the (differential) diagnosis of multiple sclerosis (MS) and clinically isolated syndrome (CIS).4,–,7 In addition to diagnostic purposes leading to an early and accurate diagnosis, MRI also has a prognostic value regarding the prediction of the time to conversion from CIS to MS and development of long-term disability.8,–,11

Both the 2010 and the recently introduced 2017 revisions of the McDonald diagnostic criteria for MS do not specify MRI acquisition measures such as magnetic field strength.7,12 As higher field strengths improve signal-to-noise ratio, resulting in increased image quality,13,14 some expert panel guidelines recommend brain imaging at 3T MRI for diagnostic and treatment monitoring purposes.6,15 Previous single-center and single-vendor studies have demonstrated that 3T MRI increases lesion detection in the brain, especially in (juxta)cortical, periventricular, and infratentorial regions, but little is known about the spinal cord.16,17 More importantly, the diagnostic relevance of high-field MRI remains uncertain, particularly in relation to the demonstration of dissemination in space and time (DIS and DIT) for the diagnosis of MS.

The purpose of this study was to prospectively evaluate the effect of 3T MRI on brain and spinal cord lesion detection in a multicenter and multivendor setting in patients with CIS, and subsequently assess its effect on fulfilment of the criteria for DIS and DIT according to McDonald diagnostic criteria.

Methods

Previously we reported an interim analysis on interobserver agreement on lesion detection in a subset of the then ongoing prospective CIS project.18 We now present the full follow-up of the whole cohort.

Participants

For this study, we recruited participants from 6 different MS centers from the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) network (magnims.eu) between July 2013 and September 2015.

Inclusion criteria were defined as follows: (1) for patients only: CIS suggestive of MS as defined by the International Panel on MS diagnosis7; (2) for patients only: baseline visit within 6 months after the first onset of clinical symptoms suggestive of demyelination; (3) age at baseline between 18 and 59 years; (4) no medical history of other immunologic disease, malignancy, or vascular pathology; (5) no known claustrophobia or allergy to a gadolinium-based contrast agent.

For the patients with CIS, the study protocol comprised 3 visits: baseline, first follow-up at 3–6 months, and a second follow-up at 12–15 months. Besides MRI, at all 3 time points a medical history was taken and a trained physician assessed the Expanded Disability Status Scale (EDSS). Information on oligoclonal band status was not available. In case of conversion to clinically definite MS during follow-up (i.e., the occurrence of a second clinical relapse, diagnosed by the treating neurologist) or fulfillment of the radiologic criteria for the diagnosis of MS, patients were excluded from further imaging. Healthy controls only underwent the baseline visit, as no clinical or radiologic changes were to be expected.

Standard protocol approvals, registrations, and patient consent

Each local institutional review board approved the study and all participants gave written informed consent prior to the first study activity.

MRI protocols

MRI examinations were performed for all participants at both 1.5T and 3T at all 3 visits. For each time point, the scan interval between the different field strengths was less than 72 hours. The scanning measures were based on local optimized acquisition protocols and in accordance with the MAGNIMS guidelines.6,15 Acquisition measures were comparable between field strengths. A detailed description of the acquisition protocols for the different vendors has previously been described.18 In brief, at both field strengths isotropic 3D T1-weighted imaging (T1WI) and 3D fluid-attenuated inversion recovery, axial 3 mm T2-weighted imaging (T2WI) and proton density (PD), and if available double inversion recovery brain imaging was performed at all time points. Patients received postcontrast T1 spin-echo at baseline only. Spinal cord imaging was performed for all participants at baseline only and consisted of sagittal 3 mm T1WI, T2WI, and PD sequences. For patients only, spinal cord imaging was performed after administration of a single dose of gadolinium-based contrast agent.

Lesion detection and diagnostic criteria

All scans were rated in consensus using a digital workstation (Sectra [Linköping, Sweden] IDS7 version 16.2.28) by 3 raters (M.H.J.H., M.L.d.V. or M.P.W., and F.B.) in random order, with a minimum time interval of 2 weeks between the rating of the 1.5T and the 3T scans. All T2 lesions larger than 3 mm at baseline or new at follow-up were scored according to their anatomical region (periventricular, [juxta]cortical, deep white matter, infratentorial, or spinal cord). In addition, baseline enhancing lesions in each anatomical region were reported for patients only. Subsequently, fulfilment of DIS and DIT for all 3 time points was determined according to the 2017 revisions of the McDonald criteria.12 In addition, the 2010 revisions of the McDonald criteria and the 2016 proposed MAGNIMS criteria were evaluated. Regarding clinical information, only the localization of the symptoms at onset as determined by the treating neurologist was provided. No additional information on age, sex, and center was available to the raters.

After all scans were scored separately, a side-by-side comparison of the 1.5T and 3T scans of each participant was performed (M.H.J.H., M.L.d.V.) to check for and if necessary correct artificial discrepancies between the ratings at both field strengths. For example, a lesion in the medial temporal lobe could have been identified as either periventricular or juxtacortical. To ensure consistency of the classification between the 1.5T and 3T scoring, we aligned the readings to assure that differences in lesion count were not based on such variations in interpretation of lesion location. The total number of lesions scored per field strength was not changed during this post hoc analysis.

Statistical analysis

Statistical analysis was performed using the Wilcoxon signed-rank test for continuous variables (number of lesions detected) and the McNemar test for dichotomous outcomes (diagnostic criteria) in SPSS 22.0 (IBM Corp., Armonk, NY). Statistical significance was defined as p < 0.05 and for subgroup analysis of the 5 anatomical regions p < 0.01 to correct for multiple testing.

Data availability

The data that support the findings of this study are available from the corresponding author (M.H.J.H.) upon reasonable request and approval by the MAGNIMS steering committee.

Results

Demographics

In total, 66 patients with CIS and 26 healthy controls were included in this study. The participant characteristics are described in table 1. In short, at baseline patients' mean age was 34.7 years, 71% were female, the median EDSS was 2.0, and most patients presented with a spinal cord syndrome (38%) or optic neuritis (39%). Healthy controls were 36.3 years old on average (compared to patients p = 0.80) and 62% were female (p = 0.37).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Cohort description

In total, 32 patients completed all 3 visits, 19 patients converted to definite MS before the third visit, and 15 patients became lost to follow-up due to various reasons, such as pregnancy, moving too far away from the hospital, or personal reasons.

Number of lesions

As described in table 2, the number of T2 lesions scored in patients at baseline was slightly but significantly higher at 3T compared to 1.5T, with a mean of 13.5 per patient at 1.5T (median 8, interquartile range [IQR] 3.0–18.5) and 15.3 at 3T (median 8, IQR 4.8–21.0) (p < 0.001). As figure 1 illustrates, this was driven by increased lesion detection at 3T in deep white matter, periventricular, and (juxta)cortical regions, of which the first 2 reached statistical significance. There was no difference in number of spinal cord lesions at baseline between field strengths. Only a limited number of gadolinium-enhancing lesions at baseline (mean 0.77 and 0.92 at 1.5T and 3T, respectively) and new T2 lesions at the 2 follow-up visits (mean 0.62 and 0.42 at 1.5T and 0.67 and 0.55 at 3T) were identified, without statistically significant differences between 1.5T and 3T. This led to a mean total (i.e., over the whole study period) number of T2 lesions of 14.1 at 1.5T (median 9, IQR 3.8–18.5) and 16.1 at 3T (median 10, IQR 4.8–21.5) (p < 0.001).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

Number of lesions detected per participant

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Mean number of lesions detected per participant per anatomical region

(A, B) Graphs illustrate the significantly increased detection of periventricular, (juxta)cortical, and deep white matter lesions on 3T in patients with clinically isolated syndrome at baseline (A) and throughout the total study (B) when compared to 1.5T. (C) Graph demonstrates there was no effect of field strength on lesion detection in healthy controls in any anatomical region. As the number of lesions identified in healthy controls is much lower compared to patients, the scale of the graph has been adjusted. To correct for multiple testing, statistical significance was defined as p < 0.01.

When excluding deep white matter lesions and exclusively considering lesions in regions relevant for DIS, the mean total number of lesions was lower, but a difference between the field strengths remained, with a mean of 8.27 at 1.5T (median 6, IQR 3.0–12.3) and 9.00 at 3T (median 6, IQR 2.0–13.0) (p = 0.038). This overall difference between the 2 field strengths stemmed mainly from an increase in periventricular and (juxta)cortical lesions at 3T, similar to baseline lesion counts (figure 2). The number of infratentorial and spinal cord lesions was similar at both field strengths.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Lesion detection on 1.5T and 3T

(A) Baseline fluid-attenuated inversion recovery brain imaging of a 28-year-old woman with clinically isolated syndrome presenting with optic neuritis. At 3T, more lesions were identified compared to 1.5T: periventricular lesions 6 vs 6, juxtacortical lesions 6 vs 3, and deep white matter lesions 12 vs 5. On both field strengths, no enhancing lesions were seen. This led to fulfilment of the 2017 revisions of the McDonald criteria for dissemination in space and not for dissemination in time at both 1.5T and 3T. Therefore the diagnosis of MS could not be made on both field strengths. So, even though high-field MRI increased the lesion detection of supratentorial demyelinating lesions in this patient, this did not change the diagnosis. (B) Baseline proton density spinal cord imaging of a 23-year-old man with clinically isolated syndrome, presenting with brainstem symptoms. Besides lesions in the brain, spinal cord lesions were identified on both field strengths. Even though there is a difference in image quality, an equal number of lesions were detected at 1.5T and 3T.

In 11 out of the 26 healthy controls, 1 or more T2 white matter lesions was identified, with a mean number of baseline T2 lesions per participant of 0.81 at 1.5T (median 0, IQR 0.00–1.00) and 1.04 at 3T (median 0, IQR 0.00–1.25) (p = 0.204). As table 2 and figure 1 illustrate, this concerns mostly deep white matter lesions. Only one periventricular lesion was identified at both field strengths and one cerebellar lesion at 3T.

Diagnostic criteria

As table 3 describes, approximately 1 out of 4 patients with CIS fulfilled the 2017 revisions of the McDonald criteria for MS at baseline.12 During follow-up, this increased to 40%–45%. The increased T2 lesion detection at 3T, however, did not lead to an increased number of participants fulfilling the criteria for DIS or DIT and subsequently MS at 3T. Surprisingly, there were even slightly more patients classified as DIS and DIT at 1.5T. The difference between the number of patients classified as MS at last follow-up at 1.5T and at 3T resulted from 1 patient with a juxtacortical lesion identified at baseline at 1.5T only, 1 patient with a gadolinium-enhancing brainstem lesion at baseline identified at 1.5T only, 1 patient with a gadolinium-enhancing spinal cord lesion identified at 3T only, and 2 patients with a new periventricular lesion during follow-up identified at 1.5T only (table 4).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3

Patients fulfilling the 2017 revisions of the McDonald diagnostic criteria

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 4

Patients fulfilling the 2017 revisions of the McDonald criteria for the diagnosis of multiple sclerosis (MS) at last follow-up per field strength

In addition, the 2010 revisions of the McDonald criteria and the 2016 proposed MAGNIMS criteria were evaluated.19,20 For neither of these criteria was there a difference in DIS, DIT, or MS between the 2 field strengths (details not shown).

With the very limited numbers of lesions in healthy controls, none of these participants fulfilled the diagnostic criteria for DIS and therefore no controls could be classified as radiologically isolated syndrome. As no gadolinium was administered and no follow-up scans were performed, DIT could not formally be assessed for healthy controls.

Discussion

This prospective, multicenter, and multivendor study confirms the previously reported significantly increased detection of T2 brain lesions at 3T.16,21,22 As a novel finding, we show that spinal cord lesion detection is not adversely affected by high field strength. More importantly, we show that the significantly higher cerebral lesion detection rate at 3T did not lead to an increased frequency or earlier diagnosis of MS based on either the 2010 or 2017 revisions of the McDonald diagnostic criteria. Hence, the clinical relevance of an improved lesion identification at 3T MRI is very limited in the diagnostic workup of patients with CIS.

An increased lesion detection rate at 3T was seen in periventricular, (juxta)cortical, and deep white matter regions. Contrary to previous research, in our study, 3T did not improve identification of infratentorial lesions.16 One possible explanation is that we used 3D sequences with near isotropic resolution at both field strengths, where a previous study used 5-mm-thick axial sequences.16 Our findings suggest that for detecting infratentorial lesions, optimizing acquisition protocols is more important than scheduling the patient for a 3T examination.

In contrast to previous studies,16,21,22 we also studied the performance of spinal cord imaging at 3T. Spinal cord lesions are not only relevant for the fulfilment of the criteria for DIS and DIT, but are also predictive of conversion to clinically definite MS.23,24 As spinal cord imaging is prone to artefacts related to CSF and vascular pulsation artefacts and patient motion caused by breathing and swallowing, interpretation of these images can be challenging.25 Due to increased susceptibility effects, these issues are aggravated at 3T MRI. Contrary to expectations, we found that identification of spinal cord lesions was not adversely affected by different field strength. In addition, interrater agreement for the detection of spinal cord lesions has been found to be higher at 3T compared to 1.5T.18 Our results suggest that spinal cord lesion detection does not suffer more from artefacts at 3T than at 1.5T and therefore 3T MRI can also be used for diagnostic scans in patients presenting with a spinal cord syndrome.

A tendency towards an increased detection rate of gadolinium-enhancing lesions was seen at 3T. An increased detection of enhancing lesions could be expected at 3T. As T1 relaxation times in brain tissue are increased by high field strength, the contrast between brain tissue and the T1-shortening effect of gadolinium is increased.22 This relatively increased T1 contrast between brain tissue and gadolinium enhancement makes enhancing lesions easier to detect. The relatively small number of enhancing lesions in this cohort could be an explanation for the difference in detection rate not reaching statistically significance.

Subsequent evaluation of the diagnostic criteria for MS did not result in a significant difference in patients with CIS classified as DIS or DIT between the 2 field strengths. This extends the findings from previous single-center studies19,26 and indicates that, even though 3T slightly increases the detection rate of demyelinating lesions, high-field MRI does not allow a higher number of patients with CIS to be diagnosed with MS. Therefore, diagnostic scans for patients with CIS can be acquired at either 1.5T or 3T, provided protocols are well-optimized.

However, the differences in lesion detection between 1.5T and 3T point out the relevance of the magnetic field strength in the follow-up of an individual participant. In clinical practice, the possibility exists that baseline and follow-up scans for one patient will be acquired at different vendors using different field strengths. If so, it is important to realize the effect of field strength on the detection of T2 lesions, so as not to confuse an increased or decreased lesion detection resulting from the technical properties of the scan with actual disease activity in that patient.27

Adding to the previously mentioned studies comparing 1.5T and 3T, we also recruited 26 healthy controls. This is highly relevant, as the improved image quality of high-field MRI allows not only for an increased detection of demyelinating lesions but also of nonspecific white matter lesions presumably due to ischemic small vessel disease, which occurred in ±40% of our control group. In CIS and even in established MS, it is not always possible to differentiate disease-specific pathology from white matter lesions related to age or comorbidity, but such nonspecific focal lesions can be analyzed in healthy controls. Overall, no statistically significant difference in lesion detection between the 2 field strengths could be demonstrated for the healthy controls. However, a tendency towards an increase in deep white matter lesions was seen. These nonspecific lesions could also in part explain the higher detection rate of deep white matter lesions in patients with CIS. On the other hand, there was no effect of 3T on identification of lesions in the anatomical regions relevant for DIS in healthy controls and imaging at high field strength did not lead to any healthy control being classified as a radiologic isolated syndrome. These results in healthy controls support the conclusion in patients with CIS that for diagnostic purposes 1.5T and 3T vendors perform similarly.

Beyond high-field MRI, various aspects of MS lesion detection are also being evaluated on ultra-high-field MRI.28,–,30 It remains uncertain whether the benefit of a further improved signal-to-noise ratio and an increased resolution will be of clinical relevance. As to be expected, 7T increases the detection rate of T2 lesions, especially for cortical gray matter lesions.31 It remains to be evaluated if this will influence the fulfilment of the diagnostic criteria for MS in multicenter studies.

Taken together, even though there is a slightly increased detection of periventricular and (juxta)cortical lesions at 3T compared to 1.5T, this does not affect the diagnosis for patients with CIS suggestive of MS. Adding to this the similar performance in detection of spinal cord lesions and gadolinium-enhancing lesions, there is no real added clinical benefit in opting for either one of the field strengths. Altogether, 3T has no added value in the diagnostic workup of patients with CIS.

Author contributions

The study was designed by I.D.K., M.P.W., and F.B. Data were collected by M.H.J.H., J.B., I.D.K., N.C., E.S., M. Andelova, M. Amann, J.M.L., P.P., J.K., C.O.-G., O.C., C.G., C.L., M.P.W., and F.B. Analysis of the data was performed by M.H.J.H., M.L.d.V., M.P.W., and F.B. Statistical analysis was done by M.H.J.H. and B.I.L.-W. The manuscript was drafted by M.H.J.H. and all other authors critically revised the manuscript for important intellectual content.

Study funding

This study has received funding from a program grant (14-358e) from the Dutch MS Research Foundation (Voorschoten, the Netherlands).

Disclosure

M. Hagens, J. Burggraaff, I. Kilsdonk, M. de Vos, N. Cawley, and E. Sbardella report no disclosures relevant to the manuscript. M. Andelova received travel and conference fees support from Novartis and Biogen. M. Amann and J. Lieb report no disclosures relevant to the manuscript. P. Pantano has received funding for travel from Novartis, Genzyme, and Bracco and speaker honoraria from Biogen. B. Lissenberg-Witte reports no disclosures relevant to the manuscript. J. Killestein has accepted speaker and consultancy fees from Merck-Serono, Teva, Biogen, Genzyme, Roche, and Novartis. C. Oreja-Guevara received honoraria as speaker from Biogen-Idec, Roche, Merck-Serono, Teva, Genzyme, and Novartis. O. Ciccarelli is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and serves as a consultant for Biogen, Roche, Teva, Genzyme, and Novartis. C. Gasperini received fees as speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, and Merck-Serono, and received a grant for research by Teva. C. Lukas holds an endowed professorship supported by the Novartis Foundation, has received consulting and speaker's honoraria from Biogen-Idec, Bayer Schering, Novartis, Sanofi, Genzyme, and TEVA, and has received research scientific grant support from Merck-Serono and Novartis. M. Wattjes serves as a consultant for Roche, Novartis, and Biogen. F. Barkhof serves as a consultant for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, Roche, Synthon BV, and Jansen Research. Go to Neurology.org/N for full disclosures.

Acknowledgment

The authors thank the following MAGNIMS steering committee members for their contribution to the study design and interpretation of the data: Tarek Yousry, MD, PhD (Queen Square MS Centre, UCL Institute of Neurology); Nicola De Stefano, MD, PhD (University of Siena); Christian Enzinger, MD, PhD (Medical University of Graz); Massimo Filippi, MD, PhD (San Raffaele Scientific Institute, Vita-Salute San Raffaele University); Maria A. Rocca (San Raffaele Scientific Institute, Vita-Salute San Raffaele University); Jette L. Frederiksen, MD, PhD (Glostrup Hospital and University of Copenhagen); Ludwig Kappos, MD, PhD (University of Basel); Jacqueline Palace, MD, PhD (University of Oxford Hospitals Trust); Alex Rovira, MD, PhD (Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona); Jauma Sastre-Garriga, MD, PhD (Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona); Hugo Vrenken, MD, PhD (MS Centre VU University Medical Centre Amsterdam).

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • The Article Processing Charge was funded by VU University Medical Centre.

  • CME Course: NPub.org/cmelist

  • Received January 15, 2018.
  • Accepted in final form April 13, 2018.
  • © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Bakshi R,
    2. Thompson AJ,
    3. Rocca MA, et al
    . MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615–625.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Paty DW,
    2. Oger JJ,
    3. Kastrukoff LF, et al
    . MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180–185.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Dekker I,
    2. Wattjes MP
    . Brain and spinal cord MR imaging features in multiple sclerosis and variants. Neuroimaging Clin N Am 2017;27:205–227.
    OpenUrl
  4. 4.↵
    1. Fazekas F,
    2. Barkhof F,
    3. Filippi M, et al
    . The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999;53:448–456.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. McDonald WI,
    2. Compston A,
    3. Edan G, et al
    . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–127.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Rovira A,
    2. Wattjes MP,
    3. Tintore M, et al
    . Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: clinical implementation in the diagnostic process. Nat Rev Neurol 2015;11:471–482.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Polman CH,
    2. Reingold SC,
    3. Banwell B, et al
    . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Beck RW,
    2. Trobe JD,
    3. Moke PS, et al
    . High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 2003;121:944–949.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Fisniku LK,
    2. Brex PA,
    3. Altmann DR, et al
    . Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808–817.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Minneboo A,
    2. Barkhof F,
    3. Polman CH,
    4. Uitdehaag BM,
    5. Knol DL,
    6. Castelijns JA
    . Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004;61:217–221.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Tintore M,
    2. Rovira A,
    3. Rio J, et al
    . Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015;138:1863–1874.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Thompson AJ,
    2. Banwell BL,
    3. Barkhof F, et al
    . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–173.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Kilsdonk ID,
    2. de Graaf WL,
    3. Barkhof F,
    4. Wattjes MP
    . Inflammation high-field magnetic resonance imaging. Neuroimaging Clin N Am 2012;22:135–157.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Wattjes MP,
    2. Barkhof F
    . High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology 2009;51:279–292.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Wattjes MP,
    2. Rovira A,
    3. Miller D, et al
    . Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11:597–606.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Wattjes MP,
    2. Lutterbey GG,
    3. Harzheim M, et al
    . Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 2006;16:2067–2073.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Simon B,
    2. Schmidt S,
    3. Lukas C, et al
    . Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol 2010;20:1675–1683.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hagens MH,
    2. Burggraaff J,
    3. Kilsdonk ID, et al
    . Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: a MAGNIMS multicentre study. Mult Scler Epub 2018.
  19. 19.↵
    1. Kilsdonk ID,
    2. Barkhof F,
    3. Wattjes MP
    . 2010 revisions to McDonald criteria for diagnosis of multiple sclerosis: impact of 3-Tesla magnetic resonance imaging. Ann Neurol 2011;70:182–183.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Filippi M,
    2. Rocca MA,
    3. Ciccarelli O, et al
    . MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292–303.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Nielsen K,
    2. Rostrup E,
    3. Frederiksen JL, et al
    . Magnetic resonance imaging at 3.0 Tesla detects more lesions in acute optic neuritis than at 1.5 Tesla. Invest Radiol 2006;41:76–82.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Sicotte NL,
    2. Voskuhl RR,
    3. Bouvier S,
    4. Klutch R,
    5. Cohen MS,
    6. Mazziotta JC
    . Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol 2003;38:423–427.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Bot JC,
    2. Barkhof F,
    3. Polman CH, et al
    . Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226–233.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Sombekke MH,
    2. Wattjes MP,
    3. Balk LJ, et al
    . Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013;80:69–75.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Bot JC,
    2. Barkhof F
    . Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. Neuroimaging Clin N Am 2009;19:81–99.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Wattjes MP,
    2. Harzheim M,
    3. Lutterbey GG, et al
    . Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol 2008;255:1159–1163.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Wattjes MP,
    2. Steenwijk MD,
    3. Stangel M
    . MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol 2015;25(suppl 2):157–165.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Kilsdonk ID,
    2. Jonkman LE,
    3. Klaver R, et al
    . Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain 2016;139:1472–1481.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Sinnecker T,
    2. Kuchling J,
    3. Dusek P, et al
    . Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. EPMA J 2015;6:16.
    OpenUrl
  30. 30.↵
    1. Tallantyre EC,
    2. Dixon JE,
    3. Donaldson I, et al
    . Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology 2011;76:534–539.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. de Graaf WL,
    2. Kilsdonk ID,
    3. Lopez-Soriano A, et al
    . Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. Eur Radiol 2013;23:528–540.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
  • CME Course

More Online

CME Course

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Topics Discussed

  • Multiple sclerosis
  • MRI
  • Cohort studies

Alert Me

  • Alert me when eletters are published
Neurology: 100 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise